MedTrace Logo

A Study on Smoking-related Lung Function Abnormalities and Correlation With Serum Biomarkers in Chinese

NCT01185652 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2011-05-13

No results posted yet for this study

Summary

Tobacco-smoking causes lung function decline with airflow obstruction, which may be accelerated in persistent smokers.This would eventually lead to chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and mortality in Hong Kong and globally. Lung function decline is gradual and not appreciated by the smoker until damage is advanced, and often under-recognised in the early stages of disease by healthcare providers. Spirometry is an established lung function measurement tool, and the most simple objective method to detect lung function decline. There is literature suggesting that newer spirometric parameters, FEV3 and FEV6, which are easier to achieve in the measurement process than conventional parameters, are comparable alternatives in detecting lung function decline.

The aims of this study are:

1. to evaluate and compare lung function decline in persistent smokers and non-smokers
2. to study the usefulness of FEV3/FVC and FEV1/FEV6 in detecting lung function decline
3. to correlate symptom scores with lung function parameters
4. To correlate serum biomarker levels with respiratory symptoms and lung function parameters in smokers and non-smokers

This is a follow-up study on a territory wide cohort including smokers and non-smokers, who have undergone lung function testing in 2001-03. Subjects will be invited to have repeat lung function assessment.

The hypotheses of this study are:

1. smokers have significantly greater decline in lung function compared to non-smokers in Hong Kong Chinese;
2. newer lung function parameters are useful alternatives in detecting lung function decline
3. serum inflammatory biomarker (IL-8, TGF-β, MMP9, TIMP-1, CRP) levels correlate with respiratory symptoms and lung function parameters in smokers when compared with non-smokers

Conditions

  • Chronic Airflow Obstruction

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • David CL Lam, BSc,MBBS,PhD,FCCP,FACP,FRCP(E) · The University of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-04-30
Completion
2012-09-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01185652 on ClinicalTrials.gov